Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KN046 plus thoracic radiotherapy in unresectable stage III non-small cell lung cancer
CTR20210726Phase 2Suspended
- Sponsor
- Kanion Pharmaceutical
- Start
- Apr 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of erfonrilimab in non-small cell lung cancer (NSCLC), sponsored by Kanion Pharmaceutical. Started Apr 2021; status: suspended.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210726.